Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies with its proprietary Gene Circuit platform, announced the selection of three abstracts for an oral minisymposium and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25–30, 2025, at the McCormick Place Convention … Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025 Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.